The Impact of THC and Drugs on Psychosis and Schizophrenia

Posted: July 23, 2025

The relationship between psychoactive substances and mental health is complex, with growing evidence linking cannabis—specifically its main active components, Delta-9-tetrahydrocannabinol (Δ9-THC) and Delta-8-tetrahydrocannabinol (Δ8-THC)—and other illegal drugs to the onset and worsening of psychosis and schizophrenia. Understanding these associations is crucial for public health, especially as the potency and accessibility of these substances increase.

THC and Psychosis: Mechanisms and Risks

Delta-9-THC, the primary psychoactive ingredient in cannabis, has been shown to induce transient psychotic symptoms such as paranoia, delusions, and perceptual disturbances in both healthy individuals and those with pre-existing mental illness. Experimental studies confirm that Δ9-THC can exacerbate both positive and negative symptoms of schizophrenia, as well as cognitive deficits, particularly in vulnerable populations. The risk is dose-dependent, with higher potency and more frequent use correlating with greater likelihood of psychotic outcomes.

Delta-8-THC: Emerging Concerns

Delta-8-THC, a cannabinoid structurally similar to Δ9-THC, has gained popularity in recent years. Although marketed as less potent, case reports and systematic reviews indicate that Δ8-THC can also induce psychotic symptoms, mood lability, and cognitive impairment. Both Δ8-THC and Δ9-THC act on the same cannabinoid receptors in the brain, suggesting similar mechanisms for psychiatric risk. The lack of regulation and quality control for Δ8-THC products may further increase the risk of adverse mental health effects.

Cannabis Use and Schizophrenia Development

Longitudinal and epidemiological studies have established a consistent association between cannabis use and the later development of psychotic disorders, including schizophrenia. The risk is particularly pronounced for individuals who begin using cannabis during adolescence, a critical period for brain development. Genetic vulnerability, early exposure, and high-potency products further amplify the risk. While cannabis use alone is neither necessary nor sufficient to cause schizophrenia, it acts as a significant component cause, especially in those with other risk factors.

Worsening of Psychosis in Diagnosed Individuals

For individuals already diagnosed with schizophrenia or other psychotic disorders, continued use of cannabis—especially high-potency Δ9-THC—has been linked to earlier onset, more frequent relapses, increased symptom severity, and poorer treatment outcomes. Persistent use is associated with higher rates of hospitalization, medication non-compliance, and functional decline. These findings underscore the importance of substance use assessment and intervention in the management of psychotic disorders.

Illegal Drugs Beyond Cannabis

Other illegal substances, such as cocaine, amphetamines, and hallucinogens, are also implicated in the onset and exacerbation of psychosis and schizophrenia. These drugs can induce acute psychotic episodes and worsen existing symptoms, particularly in individuals with underlying vulnerabilities. Poly-substance use is common among people with schizophrenia, compounding the risks and complicating treatment.

Implications for Prevention and Treatment

Given the robust evidence linking THC (both Δ8 and Δ9) and other illicit drugs to psychosis and schizophrenia, prevention efforts should focus on delaying or reducing adolescent exposure, educating about the risks of high-potency products, and screening for substance use in psychiatric care. Clinicians should be vigilant in assessing both cannabis and other drug use in patients presenting with psychotic symptoms, as early intervention may improve long-term outcomes.

References

1. Bloomfield, M. A. P., et al. (2025). Convergence of Cannabis and Psychosis on the Dopamine System. JAMA Psychiatry, 82(6), 512–522. https://doi.org/10.1001/jamapsychiatry.2025.1123

2. Murray, R. M., et al. (2014). Impact of Cannabis Use on the Development of Psychotic Disorders. Biological Psychiatry, 75(8), 482–490. https://doi.org/10.1016/j.biopsych.2013.08.017

3. van Os, J., et al. (2004). Cannabis use and the risk of developing a psychotic disorder. BMJ, 329(7464), 1196–1200. https://doi.org/10.1136/bmj.38267.664086.63

4. Moore, T. H. M., et al. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. The Lancet, 370(9584), 319–328. https://doi.org/10.1016/S0140-6736(07)61162-3

5. McDonald, A., et al. (2024). Age-dependent association of cannabis use with risk of psychotic disorder. Psychological Medicine. https://doi.org/10.1017/S0033291724001234

6. Fattore, L., et al. (2025). Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review. Journal of Clinical Psychopharmacology, 45(1), 12–23. https://doi.org/10.1097/JCP.0000000000001558

7. D’Souza, D. C., et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia. Biological Psychiatry, 57(6), 594–608. https://doi.org/10.1016/j.biopsych.2004.12.006

8. Ng, C. H., et al. (2021). Problematic Drug Use Among Outpatients With Schizophrenia and Its Relationship With Quality of Life. Frontiers in Psychiatry, 12, 762988. https://doi.org/10.3389/fpsyt.2021.762988

9. Ahmed, M., et al. (2024). Differential effects of cannabis constituents on schizophrenia-related psychosis. Frontiers in Psychiatry, 15, 1386263. https://doi.org/10.3389/fpsyt.2024.1386263

10. D’Souza, D. C., et al. (2009). Cannabis and psychosis/schizophrenia: human studies. European Archives of Psychiatry and Clinical Neuroscience, 259(7), 413–431. https://doi.org/10.1007/s00406-009-0024-2

11. Hossain, M. M., et al. (2020). Substance Use Patterns and Schizophrenia Spectrum Disorders. Journal of Clinical Medicine Research, 12(12), 758–766. https://doi.org/10.14740/jocmr4380

Disclaimer

This blog post is for general informational purposes only and is not intended as medical advice for any specific individual or condition. Reading this content does not establish a therapeutic or clinician–patient relationship. Always consult your own qualified healthcare provider for personalized medical evaluation, diagnosis, or treatment.

While efforts are made to ensure accuracy, the information is provided “as is” without warranty of any kind, express or implied. No guarantee is made as to its completeness, accuracy, or freedom from errors. The author and publisher disclaim all liability for any loss or damage arising from reliance on this content.

This post may include links to external websites for convenience only. The author and publisher do not endorse or assume responsibility for external content. The author reserves the right to update, modify, or remove content at any time without notice.